Mélissa Bou-Jaoudeh
Research Subjects
Mélissa Bou-Jaoudeh has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Florian Pereme
Digital & Innovation, Product Life Group, Immeuble Colisee Gardens, 10 Av. de l’Arche Batiment C, 7eme Etage, 92400 Courbevoie, France
1 shared publication - Gabriele Piaton-Breda
ProductLife Group, Courbevoie, France
1 shared publication - Stephen Gilbert
Else Kröner Fresenius Center for Digital Health, TUD Dresden University of Technology, Dresden, Germany
1 shared publication
Latest Publications
- Open Access
- 27 February 2025
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 59 (3) , 505-518
Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design
The emergence of personalized RNA therapeutics, tailored to individual patients' genetic profiles, offers new hope for treating both common and rare diseases. This review explores regulatory aspects of N-of-1 and N-of-few approaches, providing promising treatments for ultra- or nano-rare diseases that lack established therapies. These diseases present unique challenges, as patients may represent the sole individual or a small group worldwide with a specific mutation, necessitating personalized approaches to treatment development, validation, and approval. While progress is promising, the regulatory landscape remains nascent, raising challenges in ensuring safety and industry sustainability. Artificial intelligence (AI) and automated systems, coupled with real-world evidence (RWE) monitoring, offer significant potential to address these challenges by optimizing development, manufacturing, and regulatory compliance. Drawing parallels from other regulatory domains, this review presents a design envelope framework, integrated with AI tools, to streamline the approval process and enhance the adaptability of RNA-based treatments. Case studies of individualized RNA-based treatments highlight successes and setbacks, underscoring the need for regulatory alignment. Collaborative efforts from stakeholders and regulatory authorities are essential to refine this framework for real-world application. Overall, this review emphasizes the transformative potential of personalized RNA therapeutics in advancing precision medicine.
- 27 February 2025
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 59 (3) , 505-518
Open AccessToward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design
The emergence of personalized RNA therapeutics, tailored to individual patients' genetic profiles, offers new hope for treating both common and rare diseases. This review explores regulatory aspects of N-of-1 and N-of-few approaches, providing promising treatments for ultra- or nano-rare diseases that lack established therapies. These diseases present unique challenges, as patients may represent the sole individual or a small group worldwide with a specific mutation, necessitating personalized approaches to treatment development, validation, and approval. While progress is promising, the regulatory landscape remains nascent, raising challenges in ensuring safety and industry sustainability. Artificial intelligence (AI) and automated systems, coupled with real-world evidence (RWE) monitoring, offer significant potential to address these challenges by optimizing development, manufacturing, and regulatory compliance. Drawing parallels from other regulatory domains, this review presents a design envelope framework, integrated with AI tools, to streamline the approval process and enhance the adaptability of RNA-based treatments. Case studies of individualized RNA-based treatments highlight successes and setbacks, underscoring the need for regulatory alignment. Collaborative efforts from stakeholders and regulatory authorities are essential to refine this framework for real-world application. Overall, this review emphasizes the transformative potential of personalized RNA therapeutics in advancing precision medicine.
- 26 February 2025
- Published by Morressier GmbH
Addressing the Complexity of Oligonucleotide Impurities: Analytical Methods and Regulatory Thresholds
Oligonucleotides hold great promise as therapeutics, but managing impurities is challenging due to their complex synthesis. This study reviews an | POSTER
- 26 February 2025
- Published by Morressier GmbH
Addressing the Complexity of Oligonucleotide Impurities: Analytical Methods and Regulatory Thresholds
Oligonucleotides hold great promise as therapeutics, but managing impurities is challenging due to their complex synthesis. This study reviews an | POSTER